Doryx
- Generic Name: doxycycline hyclate
- Brand Name: Doryx
- Drug Class: Tetracyclines
Doryx (Doxycycline Hyclate) side effects drug center
What Is Doryx?
Doryx MPC (doxycycline hyclate delayed-release tablets) is a tetracycline class antibiotic indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections anthrax [including inhalational anthrax (post-exposure)], alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and prophylaxis of malaria. Doryx MPC is available in generic form.
What Are Side Effects of Doryx?
Common side effects of Doryx MPC include:
- loss of appetite,
- nausea,
- vomiting,
- diarrhea,
- rash,
- photosensitivity,
- hives, and
- hemolytic anemia.
Dosage for Doryx
The usual dosage of Doryx MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.
What Drugs, Substances, or Supplements Interact with Doryx?
Doryx MPC may interact with anticoagulants, penicillin, antacids (containing aluminum, calcium, or magnesium), bismuth subsalicylate, iron-containing preparations, oral contraceptives, barbiturates, anti-epileptic drugs (AEDs), and methoxyflurane. Tell your doctor all medications and supplements you use.
Doryx During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Doryx MPC; tetracycline-class drugs can harm a fetus, but data for doxycycline are limited. Doryx MPC passes into breast milk; but the extent of absorption of the drug in breastfed infants is unknown. Breastfeeding while using Doryx MPC is not recommended.
Additional Information
Our Doryx MPC (doxycycline hyclate delayed-release tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, flu-like symptoms, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes. This reaction may occur several weeks after you began using doxycycline.
Call your doctor at once if you have:
- severe stomach pain, diarrhea that is watery or bloody;
- throat irritation, trouble swallowing;
- chest pain, irregular heart rhythm, feeling short of breath;
- little or no urination;
- low white blood cell counts--fever, chills, swollen glands, body aches, weakness, pale skin, easy bruising or bleeding;
- increased pressure inside the skull--severe headaches, ringing in your ears, dizziness, nausea, vision problems, pain behind your eyes; or
- signs of liver or pancreas problems--loss of appetite, upper stomach pain (that may spread to your back), tiredness, nausea or vomiting, fast heart rate, dark urine, jaundice (yellowing of the skin or eyes).
Common side effects may include:
- nausea, vomiting, upset stomach, loss of appetite;
- mild diarrhea;
- skin rash or itching;
- darkened skin color; or
- vaginal itching or discharge.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Doryx (Doxycycline Hyclate)
SIDE EFFECTS
Clinical Trial Experience
The safety and efficacy of DORYX Tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. DORYX Tablets, 200 mg was given orally once-a-day for 7 days and compared to doxycycline hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital C. trachomatis infection.
Adverse events in the Safety Population were reported by 99 (40.2%) subjects in the DORYX Tablets, 200 mg treatment group and 132 (53.2%) subjects in the doxycycline hyclate capsules reference treatment group. Most AEs were mild in intensity. The most commonly reported adverse events in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.
Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects
| DORYX Tablets, 200 mg N = 246 | |
| Preferred Term | n (%) |
| Subjects with any AE | 99 (40.2) |
| Nausea | 33 (13.4) |
| Vomiting | 20 (8.1) |
| Headache | 5 (2.0) |
| Diarrhea | 8 (3.3) |
| Abdominal Pain Upper | 5 (2.0) |
| Vaginitis Bacterial | 8 (3.3) |
| Vulvovaginal Mycotic Infection | 5 (2.0) |
Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.
Due to oral doxycycline’s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:
Gastrointestinal
Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development [see WARNINGS AND PRECAUTIONS]. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline- class. Most of these patients took medications immediately before going to bed [see DOSAGE AND ADMINISTRATION].
Skin
Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above [see WARNINGS AND PRECAUTIONS].
Renal
Rise in BUN has been reported and is apparently dose-related [see WARNINGS AND PRECAUTIONS].
Hypersensitivity Reactions
Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS).
Blood
Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.
Intracranial Hypertension
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline [see WARNINGS AND PRECAUTIONS] Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.
Read the entire FDA prescribing information for Doryx (Doxycycline Hyclate)
© Doryx Patient Information is supplied by Cerner Multum, Inc. and Doryx Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.